[Federal Register: November 23, 2001 (Volume 66, Number 226)]
[Notices]
[Page 58745-58746]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23no01-60]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Arthritis Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 7, 2001, from 8
a.m. to 5 p.m.
Location: CDER Advisory Committee conference room 1066, 5630
Fishers Lane, Rockville, MD.
Contact: Kathleen Reedy or LaNise Giles, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,
(for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD
20857, 301-827-7001, FAX: 301-827-6776 or e-mail: reedyk@cder.fda.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12532. Please call the
Information Line for up-to-date information on this meeting.
Agenda: The meeting will be open to the public from 8 a.m. to 9
a.m., unless public participation does not last that long, from 9 a.m.
to 5 p.m., the meeting will be closed to permit discussion and review
of trade secret and/or confidential information.
Procedure: On December 7, 2001, from 8 a.m. to 9 a.m., the meeting
will open to the public. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Written submissions may be made to the contact person by
November 17, 2001. Oral presentations from the public will be scheduled
between approximately 8 a.m. and 9 a.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before November 17,
2001, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation.
FDA regrets that it was unable to publish this notice 15 days prior
to the December 7, 2001, Arthritis Advisory Committee meeting. Because
the agency believes there is some urgency to bring this issue to public
discussion and qualified members of the Arthritis Advisory Committee
were available at this time, the Commissioner of Food and Drugs
concluded that it was in the public interest to hold this meeting even
if there was not sufficient time for the customary 15-day public
notice.
Closed Committee Deliberations: On December 7, 2001, from 9 a.m. to
5 p.m., the meeting will be closed to permit
[[Page 58746]]
discussion and review of trade secret and/or confidential information
(5 U.S.C. 552b(c)(4)).
Notice of this meeting is given under the Federal Advisory
Committee Act 5 U.S.C. app. 2).
Dated: November 15, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-29225 Filed 11-21-01; 8:45 am]
BILLING CODE 4160-01-S